Recent Updates
Recently added Catalysts
NKTX Positive Sentiment Score: 70/100

Nkarta to Participate at Upcoming Investor Conferences

Key Takeaway: Nkarta, Inc. has announced its participation in two upcoming investor conferences, the Stifel Healthcare Conference and the Evercore ISI HealthCONx Conference. Both events will feature fireside chats and offer a platform for Nkarta to discuss its engineered natural killer (NK) cell therapies. A webcast of these events will be available on Nkarta's website, providing broad access for interested parties. This engagement highlights Nkarta's advancements in developing innovative biopharmaceutical treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple investor conferences boosts visibility.
  • Showcases Nkarta's advancements in NK cell therapies.
  • Opportunity to engage with investors and stakeholders.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences:
Stifel Healthcare Conference
10:55 a.m. ET – fireside chat
Evercore ISI HealthCONx Conference
12:30 p.m. ET – fireside chat
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:

Frequently Asked Questions

What type of therapies does Nkarta develop?

Nkarta develops engineered natural killer (NK) cell therapies.

When is Nkarta participating in the Stifel Healthcare Conference?

Nkarta's fireside chat at the Stifel Healthcare Conference is at 10:55 a.m. ET.

Where can I watch Nkarta's investor conference webcasts?

Webcasts of the conferences will be available on Nkarta’s website.

What is CRISPR's role in Nkarta's therapies?

CRISPR is used in Nkarta's proprietary genome engineering technologies.

How long will the conference replays be available?

The conference replays will be archived on the website for about 90 days.

Last updated: Nov 7, 2023